Nonalcoholic Steatohepatitis Therapeutics Market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> <strong>Therapeutics</strong><br />
<strong>Market</strong> - Global Industry Analysis, Size,<br />
Share, Growth, Trends, and Forecast 2015 -<br />
2025<br />
According to a new market report published by Transparency<br />
<strong>Market</strong> Research “<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> <strong>Therapeutics</strong><br />
<strong>Market</strong> - Global Industry Analysis, Size, Share, Growth, Trends,<br />
and Forecast 2015 - 2025”, the nonalcoholic steatohepatitis<br />
(NASH) therapeutics market is anticipated to expand at a CAGR<br />
of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.<br />
The cause of NASH is yet unclear, though research is ongoing in<br />
an attempt to find effective treatments. At present, treatment of<br />
NASH focuses on regulating some of the medical conditions<br />
associated with it such as diabetes and obesity and monitoring<br />
for advancement.<br />
As with nonalcoholic fatty liver disease, people with NASH<br />
should be vaccinated against hepatitis A and B if they are not<br />
already immune. Diagnosis of NASH is often done with routine<br />
laboratory tests. Further tests help confirm the presence of<br />
NASH and exclude other types of liver disease. Imaging tests<br />
such as ultrasound, CT scan, or magnetic resonance imaging<br />
[MRI] may expose fat accumulation in the liver but cannot
differentiate NASH from other causes of liver disease that have<br />
a similar appearance.<br />
<strong>Nonalcoholic</strong> fatty liver disease (NAFLD) is a disorder<br />
categorized by excess fat in the liver of people who drink little<br />
to no alcohol. No direct cause has yet been identified, however<br />
obesity and insulin resistance are believed to have major roles.<br />
Most often, NAFLD goes relatively undetected, as a liver can<br />
remain fatty without obstructing its function. Though, NAFLD<br />
can progress into a far more severe condition known as<br />
nonalcoholic steatohepatitis (NASH), a disease characterized by<br />
inflammation and irreversible cell death.<br />
Browse Full Research Report on <strong>Nonalcoholic</strong><br />
<strong>Steatohepatitis</strong> <strong>Therapeutics</strong> <strong>Market</strong>:<br />
http://www.transparencymarketresearch.com/nonalcoholicsteatohepatitis-market.html<br />
NASH is a disease that advances over time. Over a period of ten<br />
years up to 20% of patients with NASH develop cirrhosis of the<br />
liver, and 10% die from the disease. At present, NASH is one of<br />
the leading causes of liver transplants in the U.S., with a<br />
considerable proportion of the general population currently<br />
suffering from the disease.<br />
NAFLD and NASH are both closely related to diabetes and<br />
obesity, and together are now considered as the leading cause of
liver disease in Western countries. Thus, there is an urgent need<br />
for effective treatment options for these diseases. The need for<br />
treatment is expected to propel the growth of NASH<br />
therapeutics in coming years.<br />
The NASH market is segmented based on drug type which<br />
includes potential phase III candidates such as Obeticholic acid<br />
(OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the<br />
report provides a list of the candidates in Phase I and Phase II<br />
clinical trials. Based on the drug type, Elafibranor is expected to<br />
account for a major share of this market followed by Obeticholic<br />
Acid (OCA) market and the market for Elafibranor is expected<br />
to grow at the highest CAGR.<br />
The market overview section of the report demonstrates major<br />
market dynamics such as drivers, restraints, and opportunities<br />
that influence the current and future status of the industry. The<br />
market overview section includes epidemiology of <strong>Nonalcoholic</strong><br />
steatohepatitis (NASH) by region, to provide a thorough<br />
analysis of the overall addressable global market for the NASH<br />
therapeutics. Moreover, the report provides qualitative<br />
information about diagnosis and treatment of NASH.
The report also provides important recommendations for market<br />
players and new entrants. These recommendations would enable<br />
existing market players to expand their market shares and help<br />
new companies to establish their presence in the NASH market<br />
across different regions worldwide. The report concludes with<br />
the company profiles section, which includes key information<br />
about major players in the market such as financial overview,<br />
business strategies, and recent developments.<br />
Major players in this market are Astazeneca Plc (U.K.), Intercept<br />
Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd.<br />
(Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.),<br />
Zydus Cadila (India), Immuron Ltd. (Australia), Conatus<br />
Pharmaceuticals (U.S.), and Tobira <strong>Therapeutics</strong>, Inc. (U.S.).<br />
Browse Full Press Release on <strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong><br />
<strong>Therapeutics</strong> <strong>Market</strong>:<br />
Press Release<br />
About Us<br />
Transparency <strong>Market</strong> Research (TMR) is a global market<br />
intelligence company providing business information reports<br />
and services. The company’s exclusive blend of quantitative<br />
forecasting and trend analysis provides forward-looking insight<br />
for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants use proprietary data<br />
sources and various tools and techniques to gather and analyze<br />
information.<br />
TMR’s data repository is continuously updated and revised by a<br />
team of research experts so that it always reflects the latest<br />
trends and information. With extensive research and analysis<br />
capabilities, Transparency <strong>Market</strong> Research employs rigorous<br />
primary and secondary research techniques to develop<br />
distinctive data sets and research material for business reports.<br />
Contact Us<br />
Transparency <strong>Market</strong> Research<br />
State Tower,<br />
90 State Street, Suite 700,<br />
Albany NY - 12207<br />
United States<br />
USA - Canada Toll Free: 866-552-3453<br />
Email: sales@transparencymarketresearch.com<br />
Website: http://www.transparencymarketresearch.com